Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

[1]  Sung-Bae Kim,et al.  Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial , 2023, The Lancet.

[2]  H. Iwata,et al.  Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 , 2023, Cancer Research.

[3]  D. Gautheret,et al.  Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer , 2023, Cancer Research.

[4]  Sung-Bae Kim,et al.  Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial , 2022, The Lancet.

[5]  R. Colombo,et al.  The therapeutic window of antibody drug conjugates: A dogma in need of revision. , 2022, Cancer cell.

[6]  M. Vakalopoulou,et al.  Test-time image-to-image translation ensembling improves out-of-distribution generalization in histopathology , 2022, MICCAI.

[7]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[8]  H. Iwata,et al.  Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). , 2022, Journal of Clinical Oncology.

[9]  Yan Song,et al.  Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer , 2022, Laboratory Investigation.

[10]  B. González-Farré,et al.  LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial , 2022, Annals of Oncology.

[11]  Min Hwan Kim,et al.  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.

[12]  L. Pusztai,et al.  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. , 2022, JAMA oncology.

[13]  G. Getz,et al.  Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer , 2021, Cancer discovery.

[14]  A. Vincent-Salomon,et al.  [2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]. , 2021, Annales de pathologie.

[15]  L. Carey,et al.  Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Yeon-Hee Park,et al.  BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). , 2021 .

[17]  F. Clatot,et al.  Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort , 2021, ESMO open.

[18]  Sung-Bae Kim,et al.  Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer , 2021 .

[19]  J. Barrett,et al.  Abstract PD6-01: Novel approach to HER2 quantification: Digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients , 2021 .

[20]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[21]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[22]  A. Bardia,et al.  Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study. , 2020 .

[23]  Ming Y. Lu,et al.  Data-efficient and weakly supervised computational pathology on whole-slide images , 2020, Nature Biomedical Engineering.

[24]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Hankey,et al.  Surveillance, Epidemiology, and End Results Program , 2020, Definitions.

[26]  H. R. Tizhoosh,et al.  Yottixel - An Image Search Engine for Large Archives of Histopathology Whole Slide Images , 2019, ArXiv.

[27]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[28]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[29]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Wada,et al.  A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model , 2018, Molecular Cancer Therapeutics.

[31]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[32]  Geert J. S. Litjens,et al.  Automatic color unmixing of IHC stained whole slide images , 2018, Medical Imaging.

[33]  H. Kaplan,et al.  Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010 , 2017, Breast Cancer Research and Treatment.

[34]  Meinhard Kieser,et al.  Two-stage phase II oncology designs using short-term endpoints for early stopping , 2017, Statistical methods in medical research.

[35]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[36]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[37]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[38]  T. Agatsuma,et al.  Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.

[39]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[40]  Jungsil Ro,et al.  Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[41]  K. Horgan,et al.  Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer , 2016, Breast Cancer Research.

[42]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[43]  Molly C. Kottemann,et al.  Human GEN1 and the SLX4-associated nucleases MUS81 and SLX1 are essential for the resolution of replication-induced Holliday junctions. , 2013, Cell reports.

[44]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[45]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[46]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[47]  M. Sliwkowski,et al.  Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.

[48]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[49]  Steven P. Gygi,et al.  Mammalian BTBD12/SLX4 Assembles A Holliday Junction Resolvase and Is Required for DNA Repair , 2009, Cell.

[50]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[51]  Lajos Pusztai,et al.  Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.

[52]  Marvin Lerousseau,et al.  Unsupervised Nuclei Segmentation Using Spatial Organization Priors , 2022, MICCAI.

[53]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[54]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.